
Gaush Meditech Ltd
2407.HKHKSEHealthcareMedical - Devices
最新資料
HK$4.69
+HK$0.29 · +6.59%
2407.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Xinwei Liu
- 上市以來
- 2022年12月12日
- 僱員
- 893
市場位置
日內區間
目前HK$4.69,
52週區間
目前HK$4.69,
- 開盤價
- HK$4.49
- 前收盤價
- HK$4.40
- 成交量
- 3.23萬
- 0.65× 平均值
- 平均成交量
- 4.98萬
- 日均成交量
- 市值
- 6.94億 HKD
- 貝塔
- 0
- 市場參考 1
- 50天平均值
- HK$4.9484
- 低於平均水平-5.22%
- 200天平均值
- HK$6.2699
- 低於平均水平-25.20%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 11.4億 CNY
- 本益比(TTM)
- 6.09×
- 股價淨值比(TTM)
- 0.34×
- 股價營收比(TTM)
- 0.43×
- EV/EBITDA
- 6.72×
- 盈餘收益率
- 8.96%
- 自由現金流收益率
- 10.29%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 45.87%
- 營業利益率
- 8.81%
- 淨利潤率
- 6.97%
- 股東權益報酬率
- 5.70%
- 資產報酬率
- 3.66%
- 投入資本報酬率
- 4.16%
財務健康
- 負債權益比
- 0.3×
- 流動比率
- 2.4×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 13.8億 CNY | 14.28億 CNY | 14.06億 CNY | 12.54億 CNY | 12.98億 CNY |
| 銷貨成本 | 7.47億 CNY | 7.65億 CNY | 7.15億 CNY | 6.28億 CNY | 6.89億 CNY |
| 毛利 | 6.33億 CNY | 6.63億 CNY | 6.92億 CNY | 6.25億 CNY | 6.09億 CNY |
| 研究與開發 | 9257.5萬 CNY | 7841.8萬 CNY | 5288.3萬 CNY | 4108.9萬 CNY | 2350.6萬 CNY |
| 銷售、一般及管理費用 | 4.19億 CNY | 3.78億 CNY | 3.78億 CNY | 3.34億 CNY | 3.21億 CNY |
| 營業費用 | 5.12億 CNY | 4.37億 CNY | 4.12億 CNY | 3.61億 CNY | 3.31億 CNY |
| 利息收入 | 246.4萬 CNY | 317.5萬 CNY | 657.9萬 CNY | 467.5萬 CNY | 202萬 CNY |
| 利息支出 | 1958.9萬 CNY | 3670.9萬 CNY | 5060.6萬 CNY | 4268.2萬 CNY | 8352.5萬 CNY |
| 折舊和攤銷 | 5709.6萬 CNY | 5276萬 CNY | 7596.7萬 CNY | 4487.3萬 CNY | 4388.1萬 CNY |
| 營業利益 | 1.22億 CNY | 1.97億 CNY | 2.79億 CNY | 2.46億 CNY | 2.57億 CNY |
| 淨利 | 9618.9萬 CNY | 9239.4萬 CNY | 1.74億 CNY | −3.5億 CNY | −1.9億 CNY |
公司資料更新於 2026年8月24日。
財報歷史與展望
- 最新每股收益結果
- 0.45
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
2407.HK同業公司
持有2407.HK的ETF
報告持有此股票曝險的交易所交易基金。
繼續GoAI的研究
在 GoAI 中研究2407.HKresearch.disclaimer







